The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2016Investigation of Lipid Metabolism in GBA-associated Parkinsonism
Study Rationale:
Genetic changes in the glucocerebrosidase (GBA) gene are linked to a higher risk of developing Parkinson's disease (PD) and dementia with Lewy bodies (DLB). These changes in GBA in... -
Improved Biomarkers and Clinical Outcome Measures, 2016Corneal Confocal Microscopy: A Novel Imaging Biomarker for Parkinson's Disease
Study Rationale:
We have pioneered a technique in which we can photograph nerves on the surface of the eye. This technique can be used to monitor the severity of various neurological conditions. In our... -
Target Advancement Program, 2016Assessing the Role of Glucosylceramide in Alpha-synuclein-induced Toxicity
Study Rationale:
Loss-of-function GBA1 mutations in Gaucher disease result in increased risk for Parkinson's disease (PD). Glucocerebrosidase (GCase) normally breaks down a lipid called... -
Target Advancement Program, 2016Assessing the PINK1 Pathway in Parkinson
Study Rationale:
Rare mutations in the PINK1 gene cause familial (inherited) Parkinson's disease (PD). However, it is not known if PINK1 contributes to the development of idiopathic (no known cause) PD... -
Research Grant, 2016Investigation of LRRK2 as a Regulator of Dendritic Cell Function
Promising Outcomes of Original Grant:
Myeloid cells (white blood cells) of the immune system include monocytes, neutrophils and dendritic cells found in circulation, as well as microglia (immune system... -
Research Grant, 2016Chemical Knockdown of LRRK2 by Small Molecule PROTACS
Study Rationale:
LRRK2 is a protein kinase that appears to be a key driver of some forms of Parkinson's disease (PD). Several potent, selective, brain-penetrant LRRK2 kinase inhibitors have been...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.